AML

Oncology-focused, biopharmaceutical company Celator Pharmaceuticals has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its VYXEOS, also known as CPX-351.

VYXEOS serves as an investigational product in development that can be used to treat patients affected with acute myeloid leukemia (AML) and other types of blood cancers.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

FDA has granted the designation mainly based on the successful results attained from the Phase III clinical trial of the product administered on older patients with previously untreated high-risk (secondary) AML.

Under the trial, the product could effectively treat adults affected with therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Celator Pharmaceuticals CEO Scott Jackson said: "We are very happy the FDA granted Breakthrough Therapy designation for VYXEOS.

"We look forward to working with the FDA to bring VYXEOS to patients as quickly as possible."

"The breadth of the designation includes all adults with t-AML and AML-MRC and is encouraging since AML patients are in need of advancements in treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We look forward to working with the FDA to bring VYXEOS to patients as quickly as possible."

In the trial, the median overall survival for patients treated with VYXEOS was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favour of VYXEOS.

Later this year, Celator intends to submit a new drug application (NDA) to the FDA.

Image: Bone marrow aspirate demonstrating acute myeloid leukemia. Photo: courtesy of VashiDonsk / Wikipedia.